uPAR Informations sur la molécule
Molecule Name
Urokinase plasminogen activator surface receptor
Alias de la molécule
uPAR,PLAUR,CD87,MO3
Drug Development Progress
Nombre de médicaments cliniques7
Nombre de médicaments commercialisés0
Phase de R&D la plus avancéePhase 3 Clinical
Alias de la cible
Monocyte activation antigen Mo3，U-PAR，uPAR，CD87，Urokinase-Type Plasminogen Activator (UPA) Receptor，URKR，U-Plasminogen Activator Receptor Form 2，CD87 Antigen，Plasminogen Activator， Urokinase Receptor，MO3
Contexte de la molécule
Urokinase plasminogen activator surface receptor (U-PAR) is also known as PLAUR, Monocyte activation antigen Mo3, CD antigen CD87. PLAUR contains three UPAR/Ly6 domains. U-PAR is expressed in neurons of the rolandic area of the brain (at protein level) and is also expressed in the brain. PLAUR / CD87 interacts with MRC2, SRPX2 and SORL1. PLAUR / UPAR acts as a receptor for urokinase plasminogen activator and plays a role in localizing and promoting plasmin formation. U-PAR mediates the proteolysis-independent signal transduction activation effects of U-PA.
uPAR Liste de produits
You Have Viewed 0 Of 0 Results
Informations sur les médicaments cliniques
| Nom anglais | Code de recherche | Phase de R&D | Entreprise | Indication | Essai clinique |
|---|---|---|---|---|---|
| Gallium-68 NOTA AE105 | CS-001; 68Ga-NOTA-AE105 | Phase 3 Clinical | Curasight Aps, Rigshospitalet | Bone metastases; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Genital Neoplasms, Female; Glioblastoma; Hair Diseases; Head and Neck Neoplasms; Mesothelioma; Mouth Neoplasms; Neoplasms; Neuroendocrine Tumors; Oropharyngeal Neoplasms; Prostatic Neoplasms; Urinary Bladder Neoplasms | Details |
| WAL0921 | WAL0921; WAL-0921; WAL 0921 | Phase 2 Clinical | Walden Biosciences Inc | Diabetic Nephropathies; Glomerulonephritis, IGA; Glomerulonephritis, Membranous; Glomerulosclerosis, Focal Segmental; Kidney Diseases; Nephrosis, Lipoid; Renal Insufficiency, Chronic | Details |
| 64Cu-DOTA-AE105 | 64Cu-DOTA-AE105 | Phase 2 Clinical | Rigshospitalet | Breast Neoplasms; Prostatic Neoplasms; Urinary Bladder Neoplasms | Details |
| FG-001 | FG001; FG-001 | Phase 2 Clinical | FluoGuide AS | Brain Neoplasms; Glioma; Head and Neck Neoplasms; Low-grade Glioma; Lung Neoplasms; Meningioma | Details |
| MNPR-101-Lu177 | MNPR-101-PCTA-177Lu; MNPR-101-Lu177 | Phase 1 Clinical | Monopar Therapeutics Inc | Carcinoma, Transitional Cell; Colorectal Neoplasms; Lung Neoplasms; Ovarian Neoplasms; Pancreatic Neoplasms; Solid tumours; Stomach Neoplasms; Triple Negative Breast Neoplasms; Urinary Bladder Neoplasms | Details |
| MNPR-101-Zr | MNPR-101-Zr; MNPR-101-DFO*-89Zr | Phase 1 Clinical | Monopar Therapeutics Inc, Northstar Medical Radioisotopes Llc | Carcinoma, Transitional Cell; Colorectal Neoplasms; Lung Neoplasms; Neoplasms; Ovarian Neoplasms; Pancreatic Neoplasms; Solid tumours; Stomach Neoplasms; Triple Negative Breast Neoplasms; Urinary Bladder Neoplasms | Details |
| KMHH-03 | KMHH-03; KMHH03 | Phase 1 Clinical | Beijing Kangming Haihui Biological Technology Co Ltd | Breast Neoplasms | Details |